SEC Company Response from Oyster Point Pharma, Inc. (CIK 0001720725) — May 12, 2020
Oyster Point Pharma, Inc. (CIK 0001720725)
Date: May 12, 2020 · CIK: 0001720725 · Accession: 0001193125-20-140567
AI Filing Summary & Sentiment
File numbers found in text: 333-238194
Letter
J.P. Morgan Securities LLC
383 Madison Avenue
New York, New York 10179
Cowen and Company, LLC
599 Lexington Avenue
New York, New York 10022
Piper Sandler & Co.
345 Park Avenue, Suite 1200
New York, NY 10154
May 12, 2020
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Oyster Point Pharma, Inc.
Registration Statement on Form S-1
File No. 333-238194
Acceleration Request
Requested Date: May 14, 2020
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Oyster Point Pharma, Inc. (the “Company”) for acceleration of the effective date of the above-referenced Registration Statement, requesting effectiveness as of 4:00 P.M., Eastern Time, on May 14, 2020, or at such later time as the Company or its outside counsel, Cooley LLP, may request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Pursuant to Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that there will be distributed to each underwriter or dealer, who is reasonably anticipated to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Signature Page Follows]
Very truly yours,
J. P. MORGAN SECURITIES LLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Piper Sandler & Co. 345 Park Avenue, Suite 1200 New York, NY 10154 May 12, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Oyster Point Pharma, Inc. Registration Statement on Form S-1 File No. 333-238194 Acceleration Request Requested Date: May 14, 2020 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Oyster Point Pharma, Inc. (the “Company”) for acceleration of the effective date of the above-referenced Registration Statement, requesting effectiveness as of 4:00 P.M., Eastern Time, on May 14, 2020, or at such later time as the Company or its outside counsel, Cooley LLP, may request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Pursuant to Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that there will be distributed to each underwriter or dealer, who is reasonably anticipated to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus. We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. [Signature Page Follows] Very truly yours, J. P. MORGAN SECURITIES LLC By: /s/ Benjamin H. Burdett Authorized Signatory COWEN AND COMPANY, LLC By: /s/ Mariel Healy Authorized Signatory PIPER SANDLER & CO. By: /s/ Neil Riley Authorized Signatory